21-Drugs for Pulmonary Disorders Flashcards
Bronchiolar smooth muscle input
controlled by ANS, sympathetic stimulates beta-2 adrenergic receptors (bronchodilation)
Major features of asthma (3)
- variable airway obstruction
- airway inflammation
- airway irritability
methacholine and histamine are responsible for __________ and increased ___________
airway inflammation
fall in FEV (forced expired volume)
common causes of asthma (5)
- air pollutants
- allergens
- chemicals and food
- resp infections
- stress
what are the 2 goals of therapy for asthma?
- reduce the intensity and frequency of asthma symptoms
2. decrease the risk of adverse effects associated w asthma
reducing the intensity and frequency of asthma symptoms means:
reducing symptoms, need for short acting beta-agonist (<=2x/w), reduce night time awakening, optimize lung function, participate in formal activities
decreasing risk of adverse effects includes
preventing recurrent exacerbations and need for emergency/hospital c are, preventing poor lung development in children and loss of function in adults, optimizing pharmacotherapy w little to no adverse effects
2 strategies for pharmacological management of asthma and their drug classes:
- relievers
- SA beta-adrenergic agonists
- muscarinic antagonists - controllers
- glucocorticoids
- LA beta-adrenergic agonists
- leukotriene antagonists and lipoxygenase inhibitors
- methylxanthines (PDE inhibitors)
- IgE antibodies
Mast cell stabilizers
briefly, how is histamine produced during asthmatic response
Allergen binds to IgE receptor, Gq receptor releases 2nd messenger, IP3 (cleaved by PIP2) and increases Ca, mast cell degranulation, and histamine release = bronchoconstriction
briefly, how are Leukotrienes produced during asthmatic response
Allergen binds to IgE receptor, Gq releases 2nd messenger IP3, cleaved by PIP2, releaseing Ca activating phospholipase A2
phospholipase A2 converts arachadonyl ester into AA, AA converts into leukotrienes via 5-lipoxygenase (and PGs through COX1 and 2)
when leukotrienes and histamine act on the receptors (Gq) of SM on bronchioles what occurs
bronchoconstriction
Beta 2 adrenergic agonists: action, routes, adverse
1st line therapy:
bronchodilator (SABA or LABA)
- binds to Gs proteins on SM of bronchioles to release cAMP and sequester Ca in endoplasmic reticulum (BONUS! hyperpolarize cell w K+ eflux)
PO (LABA), inh(SABA/LABA), neb (severe attack)
Adverse: tremor tachycardia (sympathetic syimulaiton)
Anticholinergic drugs: action, routes, adverse
- muscuarining antagonists 2nd line therapy: (only works for 2/3 pt.s, good for COPD, chronic bronchitis) - use w pt. w cardiovascular concern - few adverse can combine w SABA
Airway inflammation in asthma, main mediators
inflammatory cytokines from transcription factors produce eosinophils (increases production, recruitment, and survival and secretes cytotoxic, inflammatory, and bronchoconstrict)
glucocorticoids: action, use, adverse
- suppress inflammation (inhibit COX2), hyper-responsiveness, obstruction, and prevent attacks
- does NOT dilate bronchioles
- ## works at cell membrane and DNA t bring to GCSr and GRE to downregulate gene producing mediators OR inactivate transcription factors
Leukotrienes Receptor Antagonists (LTRA): action,
competitive antagonist, induces bronchodilator and immunomodulatory effects
- can sue in combo w glucocorticoids, weaker than beta-2 adrenergic antagonists
PO, chewable form adverse: nausea, headache
Mast cell stabilizers: use
- prevent allergen-induces A metabolization (decrease leukortienes) and prevents mast cell degranulation (decrease histamine and bronchoconstrictors)
- no bronchodilatory effect, prevent constriction in response (take before exposure to antigen)
- Martha’s damn cat